{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"}]}],"title":"GH level < 2.5 μg/L"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}],"title":"GH level >2.5 μg/L"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"}],"units":"Participants"}],"description":"GH (growth hormone) levels measured on Day 84 in patients with acromegaly","groups":[{"description":"CAM2029 (octreotide FluidCrystal® injection depot) 10 mg, subcutaneous injection every two weeks\n\noctreotide FluidCrystal® injection depot","id":"OG000","title":"CAM2029 10 mg q2w (Acromegaly)"},{"description":"CAM2029 (octreotide FluidCrystal® injection depot) 20 mg, subcutaneous injection once monthly\n\noctreotide FluidCrystal® injection depot","id":"OG001","title":"CAM2029 20 mg q4w (Acromegaly)"}],"paramType":"NUMBER","populationDescription":"Pharmacokinetic population (5 acromegaly patients)","reportingStatus":"POSTED","timeFrame":"Day 84","title":"CAM2029 Effect on Growth Hormone (GH) (Acromegaly)","type":"SECONDARY","unitOfMeasure":"participants"}